ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+

A week after announcing 2024 full-year and fourth-quarter results, the firm says its corporate name will be Niagen Bioscience Inc. starting 19 March. It stated in its latest results that during 2024 it launched Niagen Plus line of pharmaceutical-grade Niagen.

ChromaDex rolled out Rx nicotinamide adenine dinucleotide products in August, along with a test kit for providers and consumers. (Source: CHromaDex)
Key Takeaways
  • Firm said its corporate name will be Niagen Bioscience Inc. starting on 19 March

ChromaDex Corp. is changing its name to better reflect its transition from relying on revenues from nicotinamide adenine dinucleotide (NAD+)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Over The Counter: Seizing The GLP-1 Wellness Opportunity, With Kerry Group’s Mathieu Millette

 
• By 

HBW Insight speaks to Kerry Group's RDA director for digestive health, Mathieu Millette, about the opportunity represented by the global trend for GLP-1 agonists for consumer health.

AstaReal Launches Membralife Supplement Following CEO Change

 
• By 

Designed to help moisturize the body’s mucous membranes, the Membralife supplement is now available in Sweden. The launch comes with AstaReal now under new management following the appointment of Daniel Flodqvist as CEO.

People On The Move: Appointments At Kenvue, EFSA, FSE

 
• By 

A round-up of the latest people moves: Kenvue names APAC president; EFSA nominates executive director; Food Supplements Europe elects board.

Danone Acquires Belgian Firm Marketing Gut Health Supplement in US

 
• By 

Danone moves into dietary supplements space with deal for The Akkermansia Company marketing patented biotic strain in US, Europe and Asia.

More from HBW Insight

Consumers More Often Choosing Private Label First

 

First Insight report from survey conducted in April with 1,267 US consumers notes that the Private Label Manufacturers Association recorded private label sales increasing by nearly 4% in 2024 to a record $271bn.

Private Label ‘Smart Imitation’ Of National Brands’ Packaging Not So Wise In US OTC Drug Sector

 

First Insight survey with 1,267 US consumers showed 44% are more likely to try a private label product “marketed as a dupe of a high-end product.” Providers of OTC drugs as well as other medical products in US would tread on thin regulatory ice with the practice.

People In US Consumer Health News: Bayer North America Treasurer Takes On CFO Role, Too

 

Bayer North America CFO with firm since 2008; Cosette VP for quality, regulatory affairs; FDA labeling review official joins ProPharma; Lifecykel, UFC veterans launch Mongolian training camp; and Beverly Hills surgeons offer skin care supplement.